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Additional SourcesDiagnosis
• Due to the progressive, debilitating 
nature of MS. It takes a 
multidisciplinary approach to 
successfully care for an individual 
with MS (Sammarco, Logan, 
Remington, 2018).
• Prompt diagnosis and start of 
treatment is ideal in managing 
exacerbations and delaying the 
progression of MS. The goal is to get
to diagnosis within 5 years (Saguil, 
Kane, & Farnell, 2014).
• It is important to rule out any other
possible conditions because there
are many that may mimic MS 
(Sammarco, Logan, Remington, 2018).
• Once there is a diagnosis of MS, it is 
important to start DMTs. The DMTs 
should be monitored by a specialist, 
usually a neurologist (Capriotti, 
Noel, & Brissenden, 2018).
• DMTs help to slow the progression
and decrease the disease activity of
MS, but symptom management is 
also needed so the individual can 
optimally live their lives (Sammarco, 
Logan, Remington, 2018).
• Educating the individual and the 
family about the MS diagnosis, 
treatments, and available resources 
is very important. It will help them
understand the disease and what
they could expect in the future.
Multiple Sclerosis (MS) is a chronic 
and progressive central nervous 
system (CNS) disease with a largely 
unknown etiology. It is a 
autoimmune demyelinating disorder 
that causes inflammation and 
scarring on the myelin sheaths of 
neuronal axons. Because it affects 
the CNS, it has many debilitating 
signs and symptoms that involve the 
sensory, motor, cognitive, and 
autonomic systems (Capriotti, Noel,
& Brissenden, 2018). 
• It is one of the most common 
causes of long-term disability 
for young adults in the United 
States (Capriotti, Noel, & 
Brissenden, 2018). 
• It affects around one million 
people in the U.S. and up to 2.5 
million in the world (Maloni, 
2018). 
• It affects women more than 
twice as much as men (Tur
&Thompson, 2015).
• The median age of onset is 
around 29 years old 
(Wingerchuk & Carter, 2014). 
• Cost associated with MS are 
more than 50,000 dollars per 
year per person (Saguil, Kane,
& Farnell, 2014).
MS has been very visible to me for 
as long as I could remember. As a 
child I remember asking my parents 
why a young individual with MS was 
in a wheelchair. In high school and 
college, I ran races and raised money 
for MS research.  The last eight years 
I have worked primarily as a 
neurological nurse and have seen 
and taken care of many MS patients. 
The strength and courage of  
individuals with MS  is what 
motivated me to learn more about 
the disease and share it with others. 
Otterbein University, Westerville, Ohio
Table 1. Disease Courses of Multiple Sclerosis Implications for Care
• Multiple Sclerosis is a debilitating 
disease of the CNS that affects 
people in the prime of their lives.
• Accurate diagnosis and treatment 
followed by great interdisciplinary 
care is needed for a person with MS. 
Not only to slow the progression of 
the disease, but to help prevent 
disability and treat symptoms so 
that they can live a more fulfilled 
life. 
• There is need for more research not
only for more effective treatments, 
but for what causes MS. Without 
knowing what the cause is, it limits 
the possible treatment options 
Conclusions
Significance of 
Pathophysiology
• First symptoms are commonly unilateral 
optic, motor, or sensory deficits. These 
include optic neuritis, weakness, balance 
problems, and numbness/tingling
(Capriotti, Noel, & Brissenden, 2018).
• The optic and cerebellar nerves are
heavily myelinated and thus are the first 
to be attacked (Capriotti, Noel, & 
Brissenden, 2018). 
• A unique sign of MS is the Lhermitte sign 
which is a jolt-like sensation that moves 
down the spine with the flexion of the 
neck (Saguil, Kane, & Farnell, 2014).
• Uhthoff sign is also unique to MS and is
the worsening of symptoms when the 
body experiences a rise in core body 
temperature (Saguil, Kane, & Farnell, 
2014).
• A full list of signs and symptoms can be
seen in Table 2. 
• There are several risk factors that seem to contribute to activation of the 
autoimmune response (Sammarco, Logan, Remington, 2018). These risk factors 
include genetic predisposition, heavy metal exposure, viral infections, and even 
higher latitudes (Capriotti, Noel, & Brissenden, 2018). 
• MS varies throughout the course of the disease. It usually starts with periods of 
neurological impairment followed by remission. As it progresses, it can become 
continuously and irreversibly debilitating (Capriotti, Noel, & Brissenden, 2018). 
• The various disease courses can be seen  in table 1.
Remitting Relapsing Multiple Sclerosis (RRMS)
• The most common type with about 85 percent of MS falling in this category 
(Sammarco, Logan, Remington, 2018).
• Characterized by periods of worsening neurological symptoms followed by recovery 
and remission (Sammarco, Logan, Remington, 2018).  
Primary Progressive Multiple Sclerosis (PPMS)
• Continuous worsening without remission after onset (Sammarco, Logan, Remington, 
2018).
Progressive Relapsing Multiple Sclerosis (PRMS)
• Continual neurological deterioration with episodes of worsening (Capriotti, Noel, & 
Brissenden, 2018). 
Secondary Progressive Multiple Sclerosis ( SPMS)
• Most RRMS transition to this continually progressive form (Capriotti, Noel, & 
Brissenden, 2018). 
• There is no single test or clinical presentation that is specifically diagnostic of MS 
(Capriotti, Noel, & Brissenden, 2018). 
• The first suspected clinical presentation of possible MS is called clinically isolated 
syndrome (CIS) and is not enough for diagnosis of MS (Sammarco, Logan, 
Remington, 2018).
• Diagnosis of MS must include “two neurologic deficits separated in time and space, 
in the absence of fever, infection, or competing etiologies” (Saguil, Kane, & Farnell, 
2014).
• The neurologic deficits must be in two separate parts of the CNS, last longer than 24
hours, and happened at least one month apart. All other etiologies must also be 
ruled out (Sammarco, Logan, Remington, 2018). 
• Magnetic Resonance Imaging (MRI) is the gold standard for diagnostic imaging with
evidence of possible MS (Saguil, Kane, & Farnell, 2014).
• These diagnostic guidelines are based on the McDonald MS diagnostic criteria. The 
revised version also includes new criteria that includes new sophisticated MRI 
testing to help speed up diagnosis (Sammarco, Logan, Remington, 2018).
• Other helpful diagnostic and treatment tests include evoked potential testing to 
measure response of specific sensory pathways to stimulus and cerebrospinal fluid 
analysis for specific immune system proteins (Capriotti, Noel, & Brissenden, 2018).
Signs Symptoms
• Visual deficits (unilateral at 
onset)
• Ataxia
• Spasticity
• Decreased sensation 
• Muscle weakness, decreased 
strength
• Nystagmus   
*ALL SIGNS AND SYMPTOMS 
RELATED TO CNS IMPAIRMENT 
(Saguil, Kane, & Farnell, 2014).
• Fatigue 
• Sensory Impairment including 
numbness and paresthesia (early 
complaint)
• Gait disturbances/Incoordination
• Weakness
• Visual disturbances
• Heat sensitivity
• Pain
• Depression (more common) or 
Euphoria 
• Dizziness
• Hearing loss or tinnitus
• Urinary symptoms    
Pathophysiology
• Although the cause of MS is unknown, it thought to be a immune- mediated 
disease. Individuals that are susceptible to MS through various risk factors,  
including genetic predisposition, are exposed to an antigen that starts a
immune response that causes inflammation and ultimately destruction of the 
myelin sheath that cover neuronal axons (Sammarco, Logan, Remington, 2018).
• TH1 cells are activated by an antigen in the periphery where they proliferate 
and release cytokines and metalloproteinases that let the T cells cross the 
blood brain barrier into the CNS (Sammarco, Logan, Remington, 2018). 
• The T cells (TH2) in the CNS are presented with myelin proteins that resemble 
the antigen in the periphery. This reactivates the T- cells and along with B cells, 
CD8+ T cells, and macrophages starts an inflammatory response that ends in 
the destruction of the myelin sheath (Sammarco, Logan, Remington, 2018).   
• This inflammation causes demyelination of the CNS neuronal axons and leads to 
axonal damage that causes neurological decline (Sammarco, Logan, Remington, 
2018).
• The myelin heals after an exacerbation, but is eventually replaced by a fibrotic 
scar tissue (sclerosis). These are the white plaques commonly seen on MRI 
(Capriotti, Noel, & Brissenden, 2018). 
Table 2.
• Knowing the pathophysiology of MS
helps one understand the process in
which the damage is being done to 
create the clinical signs and symptoms of 
MS. 
• The process is thought to be autoimmune
with the body turning on itself and
destroying the myelin sheaths of the CNS 
nerves. So the main goal of treatment is 
to stop this from taking place. 
• Majority of those with MS have RRMS, 
and up to 85% will have an exacerbation 
of severe symptoms (Saguil, Kane, & 
Farnell, 2014).
• With these exacerbations, the
inflammation is actively injuring the 
myelin sheath as well as the axon. The 
most effective way to treat this is to help 
deescalate the inflammatory process 
with corticosteroids. When this is not
enough, plasma transfers might be 
needed (Saguil, Kane, & Farnell, 2014).
• Since MS is considered an autoimmune 
disease, treatment involves 
immunomodulators, specifically disease 
modifying therapies (DMT) (Capriotti, 
Noel, & Brissenden, 2018).
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